High efficacy of combination therapy using PI3K/AKT inhibitors with androgen deprivation in prostate cancer preclinical models

RB Marques, A Aghai, CMA de Ridder, D Stuurman… - European urology, 2015 - Elsevier
Abstract Background The phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K)/AKT
pathway is frequently activated during prostate cancer (PCa) progression through loss or …
被引用次数：118 相关文章

High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models

RB Marques, A Aghai, CMA de Ridder… - European …, 2015 - pubmed.ncbi.nlm.nih.gov
Background The phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K)/AKT pathway is
frequently activated during prostate cancer (PCa) progression through loss or mutation of …

High efficacy of combination therapy using PI3K/AKT inhibitors with androgen deprivation in prostate cancer preclinical models

R Marques, A Aghai, C de Ridder… - … : Official Journal of the …, 2015 - repub.eur.nl
Background The phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K)/AKT pathway is
frequently activated during prostate cancer (PCa) progression through loss or mutation of …

High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models

RB Marques, A Aghai, CMA de Ridder, D Stuurman… - European Urology, 2015 - infona.pl
The phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K)/AKT pathway is frequently
activated during prostate cancer (PCa) progression through loss or mutation of the …

[引用][C] High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models

RB Marques, A Aghai, CMA de Ridder, D Stuurman… - European Urology, 2015 - cir.nii.ac.jp
High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation
in Prostate Cancer Preclinical Models | CiNii Research CiNii 国立情報学研究所 学術情報 …

High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.

RB Marques, A Aghai, CMA de Ridder… - European …, 2014 - europepmc.org
Background The phosphatidylinositol-4, 5-bisphosphate 3-kinase (PI3K)/AKT pathway is
frequently activated during prostate cancer (PCa) progression through loss or mutation of …